Quick Answer
A major Lancet Psychiatry study found semaglutide (Ozempic) reduces worsening depression by 44% and anxiety by 38%. Indian patients with obesity or diabetes may gain significant mental health benefits from GLP-1 therapy.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
A landmark study published in The Lancet Psychiatry has found that semaglutide — the active ingredient in Ozempic and Wegovy — dramatically reduces the risk of worsening depression and anxiety. The findings, which were reported widely including in Business Standard in India, add a powerful new dimension to what GLP-1 drugs can do for patients. If you have type 2 diabetes or obesity in India, this research is directly relevant to you.
What the Lancet Study Found
Researchers analysed data from nearly 100,000 individuals tracked through Swedish national health registers between 2009 and 2022. More than 20,000 of the participants had used GLP-1 medications at some point. The results were striking and specific to semaglutide.
During periods when patients were taking semaglutide, they showed a 44% decreased risk of worsening depression, a 38% decreased risk of worsening anxiety, and a 47% decreased risk of worsening substance use disorder. Additionally, patients on semaglutide had 42% fewer episodes of psychiatric-related hospitalisation and work absence compared to periods when they were not taking the drug. These are large effects by the standards of any medical study, particularly one involving nearly 100,000 people.
Importantly, the benefits appeared to be specific to semaglutide. Other GLP-1 medications such as exenatide and dulaglutide did not show the same significant mental health associations, which suggests that semaglutide may have a unique mechanism of action on the brain beyond its well-known effects on blood sugar and weight.
How Does Semaglutide Affect Mental Health?
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Scientists believe semaglutide works on the brain in ways that go beyond weight loss. GLP-1 receptors are not only found in the pancreas — they are also present in several brain regions involved in mood regulation, motivation, and reward processing. Semaglutide appears to modulate activity in the limbic system, which controls emotional responses, and may reduce the chronic low-grade inflammation in the brain that is increasingly associated with depression.
Another pathway involves metabolic improvement itself. Type 2 diabetes, insulin resistance, and obesity are all independently associated with higher rates of depression and anxiety — a link that is well-documented in Indian research. When semaglutide corrects these metabolic problems, it may also be correcting the physiological environment that drives mood disorders.
The finding that semaglutide reduced substance use disorder risk by 47% connects to the brain's dopamine reward system. The drug appears to quiet reward cravings — an effect researchers have observed in patients who spontaneously drink less alcohol and smoke less after starting GLP-1 therapy, without being instructed to.
Why This Matters Particularly for Indian Patients
India carries one of the world's highest burdens of both metabolic disease and mental health conditions. According to the National Mental Health Survey, over 150 million Indians need active mental health intervention. Depression and anxiety disorders are the most common diagnoses, and they remain severely undertreated — less than 30% of those who need care receive it.
At the same time, India has over 100 million people with type 2 diabetes and millions more with obesity. These two populations overlap significantly. Research consistently shows that people with diabetes are two to three times more likely to experience depression than the general population, and managing both conditions simultaneously is extremely challenging.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
For Indian patients who already qualify for GLP-1 therapy because of diabetes or obesity, the evidence now suggests they may also be receiving meaningful mental health protection. This matters for the total disease burden a patient carries — not just their blood sugar numbers, but their mood, their energy, their ability to work, and their quality of daily life.
What Should Indian Patients Do With This Information?
If you have type 2 diabetes, obesity, or metabolic syndrome — and you are also dealing with depression, anxiety, or substance use — GLP-1 therapy is now worth discussing with both your physician and a mental health professional. This is not a replacement for psychiatric care, therapy, or prescribed psychiatric medications. But for patients who already have a metabolic indication for GLP-1 drugs, the mental health data adds a meaningful additional reason to start sooner rather than later.
In 2026, access to semaglutide in India has improved significantly. Generic versions are now available from Indian manufacturers including Sun Pharma and Dr. Reddy's at approximately Rs 3,500 to Rs 6,000 per month — far more affordable than branded Ozempic. A specialist can help you identify the right dose, the right formulation, and the safest way to begin treatment given your full medical history.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. Business Standard — https://www.business-standard.com/health/ozempic-semaglutide-lowers-depression-anxiety-risk-lancet-study-126040800826_1.html 2. ScienceDaily — https://www.sciencedaily.com/releases/2026/05/260502233924.htm 3. Newsweek — https://www.newsweek.com/semaglutide-glp1-ozempic-shows-mental-health-benefits-2026-11788968
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.